Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
250 participants
Study Classification
OBSERVATIONAL
Study Start Date
2015-06-30
Study Completion Date
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
SEVERE ASTHMA IN THE COMMUNITY-
BACKGROUND Severe asthma is a common problem. In the world approximately 300 million people have asthma but it is estimated that only 5% of these patients have severe asthma. Although "severe asthma" comprises a small fraction of the entire asthmatic population its share in the total economic burden of asthma is 80 percent. In Israel the prevalence of asthma among adult patients is about 5-6% but the prevalence of severe asthma is unknown.
The definition of severe asthma has been changed during the years. Most recently in 2009 the WHO agreed on a unified definition of "severe asthma" that would fit countries of different socioeconomic development \[1\]. Severe asthma includes now 3 different groups: group one "untreated severe asthma", group two "difficult to treat severe asthma" and group three "treatment-resistant severe asthma". As all asthmatic patients in Israel have easy access to medical care, the current study will deal with the last two groups ("difficult to treat asthma" and "treatment resistant asthma").
AIMS Primary endpoints:
1. To identify the prevalence of severe asthma in the community according to the WHO definition of group two \& three.
2. To assess whether anti-IgE therapy (Omalizumab), was considered in these groups of severe asthma.
Secondary endpoints:
1. To assess factors involved in "difficult to treat asthma" according to the WHO definition. Factors as patient compliance, presence of co-morbidities, symptoms of untreated potential asthma triggers including GE reflux, post nasal drip/atopic rhino-sinusitis, and intervening medications including NSAID and beta-blockers.
2. To asses the level of asthma control, level of patient follow-up care including asthma specialist visits, periodic PFT's and asthma education.
3. To assess the fraction of patients with severe asthma that is eligible to anti-IgE therapy according to the indications of the Israeli Ministry of Health (proven asthma, uncontrolled by high dose of combined ICS+LABA inhaler therapy + at least 2 courses of systemic corticosteroids in the last year + proven atopy to at least one perennial aeroallergen + IgE level of 30-1,500 IU/ml)
DESIGN A prospective non-blinded non-randomized observation study among the population insured by Clalit Medical Services (CMS) in the Sharon- Shomron Medical District in Israel.
BACKGROUND Severe asthma is a common problem. In the world approximately 300 million people have asthma but it is estimated that only 5% of these patients have severe asthma. Although "severe asthma" comprises a small fraction of the entire asthmatic population its share in the total economic burden of asthma is 80 percent. In Israel the prevalence of asthma among adult patients is about 5-6% but the prevalence of severe asthma is unknown.
The definition of severe asthma has been changed during the years. Most recently in 2009 the WHO agreed on a unified definition of "severe asthma" that would fit countries of different socioeconomic development \[1\]. Severe asthma includes now 3 different groups: group one "untreated severe asthma", group two "difficult to treat severe asthma" and group three "treatment-resistant severe asthma". As all asthmatic patients in Israel have easy access to medical care, the current study will deal with the last two groups ("difficult to treat asthma" and "treatment resistant asthma").
AIMS Primary endpoints:
1. To identify the prevalence of severe asthma in the community according to the WHO definition of group two \& three.
2. To assess whether anti-IgE therapy (Omalizumab), was considered in these groups of severe asthma.
Secondary endpoints:
1. To assess factors involved in "difficult to treat asthma" according to the WHO definition. Factors as patient compliance, presence of co-morbidities, symptoms of untreated potential asthma triggers including GE reflux, post nasal drip/atopic rhino-sinusitis, and intervening medications including NSAID and beta-blockers.
2. To asses the level of asthma control, level of patient follow-up care including asthma specialist visits, periodic PFT's and asthma education.
3. To assess the fraction of patients with severe asthma that is eligible to anti-IgE therapy according to the indications of the Israeli Ministry of Health (proven asthma, uncontrolled by high dose of combined ICS+LABA inhaler therapy + at least 2 courses of systemic corticosteroids in the last year + proven atopy to at least one perennial aeroallergen + IgE level of 30-1,500 IU/ml)
DESIGN A prospective non-blinded non-randomized observation study among the population insured by Clalit Medical Services (CMS) in the Sharon- Shomron Medical District in Israel.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Portuguese Severe Asthma Registry: Getting Answers for Severe Asthma Patients
NCT04714567
Severe Asthma
UNKNOWN
Severe Asthma Research Program
NCT01606826
Asthma
ACTIVE_NOT_RECRUITING
Inflammation and Corticosteroid Responsiveness in Severe Asthma
NCT00180661
Asthma
COMPLETED
Allergens in Inner-City Schools and Childhood Asthma
NCT01756391
Asthma
COMPLETED
Asthma Exacerbations & Respiratory Management International Survey
NCT06652542
Acute Asthma Exacerbations
ENROLLING_BY_INVITATION
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SEVERE ASTHMA IN THE COMMUNITY- STUDY PROTOCOL-SYNOPSIS
TITLE Severe Asthma in the Community: How severe it really is and to what extent its management has been exhausted PI Shabtai Varsano M.D. Head Asthma Clinic, Head-deputy Dept. of Pulmonary Medicine.
Co-investigators Shitrit David M.D, Head Dept. of Pulmonary Medicine David Segev M.D Sharon -Shomron Medical District Headquarters, Clalit Medical Services.
SITE Asthma Care \& Education Unit, Dept of Pulmonary Medicine, Sapir Medical Center, Meir General Hospital Kfar-Sava, Israel.
BACKGROUND Severe asthma is a common problem. In the world approximately 300 million people have asthma but it is estimated that only 5% of these patients have severe asthma. Although "severe asthma" comprises a small fraction of the entire asthmatic population its share in the total economic burden of asthma is 80 percent. In Israel the prevalence of asthma among adult patients is about 5-6% but the prevalence of severe asthma is unknown.
The definition of severe asthma has been changed during the years. Most recently in 2009 the WHO agreed on a unified definition of "severe asthma" that would fit countries of different socioeconomic development \[1\]. Severe asthma includes now 3 different groups: group one "untreated severe asthma", group two "difficult to treat severe asthma" and group three "treatment-resistant severe asthma". As all asthmatic patients in Israel have easy access to medical care, the current study will deal with the last two groups ("difficult to treat asthma" and "treatment resistant asthma").
AIMS Primary endpoints:
1. To identify the prevalence of severe asthma in the community according to the WHO definition of group two \& three.
2. To assess whether anti-IgE therapy (Omalizumab), was considered in these groups of severe asthma.
Secondary endpoints:
1. To assess factors involved in "difficult to treat asthma" according to the WHO definition. Factors as patient compliance, presence of co-morbidities, symptoms of untreated potential asthma triggers including GE reflux, post nasal drip/atopic rhino-sinusitis, and intervening medications including NSAID and beta-blockers.
2. To asses the level of asthma control, level of patient follow-up care including asthma specialist visits, periodic PFT's and asthma education.
3. To assess the fraction of patients with severe asthma that is eligible to anti-IgE therapy according to the indications of the Israeli Ministry of Health (proven asthma, uncontrolled by high dose of combined ICS+LABA inhaler therapy + at least 2 courses of systemic corticosteroids in the last year + proven atopy to at least one perennial aeroallergen + IgE level of 30-1,500 IU/ml)
DESIGN:
A prospective non-blinded non-randomized observation study among the population insured by Clalit Medical Services (CMS) in the Sharon- Shomron Medical District in Israel.
PROTOCOL:
The study will include all patients at the age interval of 20-70 years with bronchial asthma treated by CMS, Sharon-Shomron district. The total population at this age interval that is insured by CMS in this district is 347,374.
A. Screening of the computerized database of CMS to detect all patients at the age interval of 20-70 years with a computerized title-diagnosis of bronchial asthma during the period of January 1st -December 31, 2011. (preliminary data shows that the total asthmatic population at this age interval is 20,651 patients (5.94% of the entire population).
B. To detect from this database the asthmatic patients that are considered to have "severe asthma" according to the level of medication that is prescribed to them (adjusted on the basis of severe/refractory asthma definition by the ATS workshop consensus 2000) \[2\].
C. To detect the fraction of patients having co-morbidities and/or potential triggers (computerized title-diagnosis) that may interfere with asthma management (WHO group two: potentially "difficult to treat severe asthma"). Severe asthmatics without these co-morbidities /triggers will be considered as having WHO group three "treatment resistant severe asthma".
D. To detect the fraction of the patients with "severe asthma" that underwent evaluation for anti IgE-therapy.
E. To evaluate a sample of the above "severe asthma" population (WHO groups two and three) in the asthma outpatient clinic in Meir Hospital (estimated on the basis of preliminary data, 200-250 patients). If the absolute number of patients in either WHO group two or group three will not exceed 150, all patients will be invited. If the number will exceed 150, then each second patient, consecutively according to the computerized list, will be invited.
F. Patients invited to the asthma outpatient clinic will be evaluated by a pulmonary physician and complete a specific questionnaire regarding asthma control level (including non-scheduled use of medical resources), medication adherence, co-morbidities, smoking history, potential asthma triggers, level of asthma education, quality of follow-up care and potential adverse events in patients receiving anti-IgE therapy that are possibly related to this specific therapy.
G. All patients will undergo post bronchodilator spirometric evaluation, assessment of blood cell counts for peripheral eosinophils, total IgE blood levels and skin testing for aeroallergens.
H. Stages F and G of this protocol will be accomplished in one visit and there will be no more outpatint visits under this study.
Inclusion criteria:
A. Age 20-70 years old
B. A computerized diagnosis-title of "bronchial asthma", at any stage of severity. A subgroup of the above asthmatic patients will be considered as having "severe asthma" according to the ATS workshop consensus definition of severe/refractory asthma, based on the level of prescribed medication criteria 2000:
C. An obligatory criteria of at least 12 month inhaler-therapy prescription of a combination of high dose corticosteroid +LABA (at least 12 inhalers of Symbicort 160/4.5 mcg OR at least 10 inhalers of Seretide 500 mcg, a year) PLUS at least one of the following criteria:
D. Prescription of SABA, either Ventolin OR Bricalin inhalers at least once a quarter of a year or at least 4 inhalers in 12 months OR at least one prescription a month of inhalation-solution of Ventolin or Bricalin a month.
E. Prescription of an oral or IM corticosteroid, at least twice in the last 12 months.
The fulfilment of the above mentioned criteria indicates that these asthmatic patients are not conrolled, according to the GINA definition of controlled asthma.
Asthmatics that potentially have "difficult to treat severe asthma" due to co-morbidities or potential triggering factors will be sub-grouped according to these criteria (criteria for potential exclusion of having "treatment resistant severe asthma"):
A. Having computerized title-diagnosis of COPD, congestive heart failure, smoking, bronchiectasis, interstitial lung disease.
B. Prescription of an oral or topical (ocular) beta-blockers.
TITLE Severe Asthma in the Community: How severe it really is and to what extent its management has been exhausted PI Shabtai Varsano M.D. Head Asthma Clinic, Head-deputy Dept. of Pulmonary Medicine.
Co-investigators Shitrit David M.D, Head Dept. of Pulmonary Medicine David Segev M.D Sharon -Shomron Medical District Headquarters, Clalit Medical Services.
SITE Asthma Care \& Education Unit, Dept of Pulmonary Medicine, Sapir Medical Center, Meir General Hospital Kfar-Sava, Israel.
BACKGROUND Severe asthma is a common problem. In the world approximately 300 million people have asthma but it is estimated that only 5% of these patients have severe asthma. Although "severe asthma" comprises a small fraction of the entire asthmatic population its share in the total economic burden of asthma is 80 percent. In Israel the prevalence of asthma among adult patients is about 5-6% but the prevalence of severe asthma is unknown.
The definition of severe asthma has been changed during the years. Most recently in 2009 the WHO agreed on a unified definition of "severe asthma" that would fit countries of different socioeconomic development \[1\]. Severe asthma includes now 3 different groups: group one "untreated severe asthma", group two "difficult to treat severe asthma" and group three "treatment-resistant severe asthma". As all asthmatic patients in Israel have easy access to medical care, the current study will deal with the last two groups ("difficult to treat asthma" and "treatment resistant asthma").
AIMS Primary endpoints:
1. To identify the prevalence of severe asthma in the community according to the WHO definition of group two \& three.
2. To assess whether anti-IgE therapy (Omalizumab), was considered in these groups of severe asthma.
Secondary endpoints:
1. To assess factors involved in "difficult to treat asthma" according to the WHO definition. Factors as patient compliance, presence of co-morbidities, symptoms of untreated potential asthma triggers including GE reflux, post nasal drip/atopic rhino-sinusitis, and intervening medications including NSAID and beta-blockers.
2. To asses the level of asthma control, level of patient follow-up care including asthma specialist visits, periodic PFT's and asthma education.
3. To assess the fraction of patients with severe asthma that is eligible to anti-IgE therapy according to the indications of the Israeli Ministry of Health (proven asthma, uncontrolled by high dose of combined ICS+LABA inhaler therapy + at least 2 courses of systemic corticosteroids in the last year + proven atopy to at least one perennial aeroallergen + IgE level of 30-1,500 IU/ml)
DESIGN:
A prospective non-blinded non-randomized observation study among the population insured by Clalit Medical Services (CMS) in the Sharon- Shomron Medical District in Israel.
PROTOCOL:
The study will include all patients at the age interval of 20-70 years with bronchial asthma treated by CMS, Sharon-Shomron district. The total population at this age interval that is insured by CMS in this district is 347,374.
A. Screening of the computerized database of CMS to detect all patients at the age interval of 20-70 years with a computerized title-diagnosis of bronchial asthma during the period of January 1st -December 31, 2011. (preliminary data shows that the total asthmatic population at this age interval is 20,651 patients (5.94% of the entire population).
B. To detect from this database the asthmatic patients that are considered to have "severe asthma" according to the level of medication that is prescribed to them (adjusted on the basis of severe/refractory asthma definition by the ATS workshop consensus 2000) \[2\].
C. To detect the fraction of patients having co-morbidities and/or potential triggers (computerized title-diagnosis) that may interfere with asthma management (WHO group two: potentially "difficult to treat severe asthma"). Severe asthmatics without these co-morbidities /triggers will be considered as having WHO group three "treatment resistant severe asthma".
D. To detect the fraction of the patients with "severe asthma" that underwent evaluation for anti IgE-therapy.
E. To evaluate a sample of the above "severe asthma" population (WHO groups two and three) in the asthma outpatient clinic in Meir Hospital (estimated on the basis of preliminary data, 200-250 patients). If the absolute number of patients in either WHO group two or group three will not exceed 150, all patients will be invited. If the number will exceed 150, then each second patient, consecutively according to the computerized list, will be invited.
F. Patients invited to the asthma outpatient clinic will be evaluated by a pulmonary physician and complete a specific questionnaire regarding asthma control level (including non-scheduled use of medical resources), medication adherence, co-morbidities, smoking history, potential asthma triggers, level of asthma education, quality of follow-up care and potential adverse events in patients receiving anti-IgE therapy that are possibly related to this specific therapy.
G. All patients will undergo post bronchodilator spirometric evaluation, assessment of blood cell counts for peripheral eosinophils, total IgE blood levels and skin testing for aeroallergens.
H. Stages F and G of this protocol will be accomplished in one visit and there will be no more outpatint visits under this study.
Inclusion criteria:
A. Age 20-70 years old
B. A computerized diagnosis-title of "bronchial asthma", at any stage of severity. A subgroup of the above asthmatic patients will be considered as having "severe asthma" according to the ATS workshop consensus definition of severe/refractory asthma, based on the level of prescribed medication criteria 2000:
C. An obligatory criteria of at least 12 month inhaler-therapy prescription of a combination of high dose corticosteroid +LABA (at least 12 inhalers of Symbicort 160/4.5 mcg OR at least 10 inhalers of Seretide 500 mcg, a year) PLUS at least one of the following criteria:
D. Prescription of SABA, either Ventolin OR Bricalin inhalers at least once a quarter of a year or at least 4 inhalers in 12 months OR at least one prescription a month of inhalation-solution of Ventolin or Bricalin a month.
E. Prescription of an oral or IM corticosteroid, at least twice in the last 12 months.
The fulfilment of the above mentioned criteria indicates that these asthmatic patients are not conrolled, according to the GINA definition of controlled asthma.
Asthmatics that potentially have "difficult to treat severe asthma" due to co-morbidities or potential triggering factors will be sub-grouped according to these criteria (criteria for potential exclusion of having "treatment resistant severe asthma"):
A. Having computerized title-diagnosis of COPD, congestive heart failure, smoking, bronchiectasis, interstitial lung disease.
B. Prescription of an oral or topical (ocular) beta-blockers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Severe Asthma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sever asthmatics in the comminity
Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
Computerized data base analysis and sampling of patients for outpatient clinic evaluation
Intervention Type
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computerized data base analysis and sampling of patients for outpatient clinic evaluation
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 20-70 years old
* A computerized diagnosis-title of "bronchial asthma", at any stage of severity.
A subgroup of the above asthmatic patients will be considered as having "severe asthma" according to the ATS workshop consensus definition of severe/refractory asthma, based on the level of prescribed medication criteria 2000:
\- An obligatory criteria of at least 12 month inhaler-therapy prescription of a combination of high dose corticosteroid +LABA (at least 12 inhalers of Symbicort 160/4.5 mcg OR at least 10 inhalers of Seretide 500 mcg, a year)
PLUS at least one of the following criteria:
* Prescription of SABA, either Ventolin OR Bricalin inhalers at least once a quarter of a year or at least 4 inhalers in 12 months OR at least one prescription a month of inhalation-solution of Ventolin or Bricalin a month.
* Prescription of an oral or IM corticosteroid, at least twice in the last 12 months.
The fulfilment of the above mentioned criteria indicates that these asthmatic patients are not conrolled, according to the GINA definition of controlled asthma.
Asthmatics that potentially have "difficult to treat severe asthma" due to co-morbidities or potential triggering factors will be sub-grouped according to these criteria (criteria for potential exclusion of having "treatment resistant severe asthma"):
* Having computerized title-diagnosis of COPD, congestive heart failure, smoking, bronchiectasis, interstitial lung disease.
* Prescription of an oral or topical (ocular) beta-blockers.
* A computerized diagnosis-title of "bronchial asthma", at any stage of severity.
A subgroup of the above asthmatic patients will be considered as having "severe asthma" according to the ATS workshop consensus definition of severe/refractory asthma, based on the level of prescribed medication criteria 2000:
\- An obligatory criteria of at least 12 month inhaler-therapy prescription of a combination of high dose corticosteroid +LABA (at least 12 inhalers of Symbicort 160/4.5 mcg OR at least 10 inhalers of Seretide 500 mcg, a year)
PLUS at least one of the following criteria:
* Prescription of SABA, either Ventolin OR Bricalin inhalers at least once a quarter of a year or at least 4 inhalers in 12 months OR at least one prescription a month of inhalation-solution of Ventolin or Bricalin a month.
* Prescription of an oral or IM corticosteroid, at least twice in the last 12 months.
The fulfilment of the above mentioned criteria indicates that these asthmatic patients are not conrolled, according to the GINA definition of controlled asthma.
Asthmatics that potentially have "difficult to treat severe asthma" due to co-morbidities or potential triggering factors will be sub-grouped according to these criteria (criteria for potential exclusion of having "treatment resistant severe asthma"):
* Having computerized title-diagnosis of COPD, congestive heart failure, smoking, bronchiectasis, interstitial lung disease.
* Prescription of an oral or topical (ocular) beta-blockers.
Exclusion Criteria
* Age \<20 or \>70 years old.
Minimum Eligible Age
20 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meir Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shabtai Varsano, M.D.
Role: PRINCIPAL_INVESTIGATOR
Head-Deputy Dept. of Pulmonary medicine. Head of Asthma Care and Education unit.
References
Explore related publications, articles, or registry entries linked to this study.
Varsano S, Israeli L, Shitrit D. "Severe-controlled" asthma 4 years later: is it still controlled? J Asthma. 2021 Aug;58(8):1102-1110. doi: 10.1080/02770903.2020.1753208. Epub 2020 Apr 27.
Reference Type
DERIVED
Varsano S, Segev D, Shitrit D. Severe and non-severe asthma in the community: A large electronic database analysis. Respir Med. 2017 Feb;123:131-139. doi: 10.1016/j.rmed.2016.12.017. Epub 2016 Dec 28.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0016-13-MMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Swiss Severe Asthma Register
NCT03984253
RECRUITING
The Effect of Asthma Flare-up Clinic After Exacerbation
NCT06201728
ENROLLING_BY_INVITATION
NA
Evaluation of a Community Pharmacist Managed Asthma Consultation Service
NCT02768623
COMPLETED
NA
The Clinical and Laboratory Phenotypes of Severe Asthma Patients in Clalit Health Services Haifa
NCT01741805
WITHDRAWN
Longitudinal Observational Study of Severe Asthma
NCT01780142
COMPLETED
International Severe Asthma Registry: Canadian Cohort
NCT04045587
RECRUITING
Epidemiology and Cytokines Analysis of Severe Asthma Patients in Taiwan
NCT02871947
UNKNOWN
Identification of Asthma Phenotypes in Severe Asthmatics
NCT01623089
RECRUITING
Clinico-biological Correlation of Severe Asthma in Children
NCT02038374
UNKNOWN
NA
Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma
NCT06223581
NOT_YET_RECRUITING
PROPE Severe Asthma Study in Egypt
NCT06283290
COMPLETED
Immune Interactions in Severe Asthma
NCT02566668
COMPLETED
A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service
NCT06261567
COMPLETED
Effects of Web-Based Education on Patient Empowerment and Asthma Control in Asthma Patients
NCT06269289
NOT_YET_RECRUITING
NA
Follow-up of Children With Severe Asthma at Adult Age
NCT05032209
UNKNOWN
Register Schweres Asthma - German Asthma Net e.V.
NCT06035289
RECRUITING
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
NCT01476059
COMPLETED
PHASE4
Asthma Symptom Perception Study
NCT06612294
RECRUITING
NA
Experience of Biologic Treatments for Severe Asthma: a Survey
NCT06903780
RECRUITING
Approach to Predict Steroid Sensitivity in Patients With Asthma
NCT00811278
COMPLETED
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
NCT02502890
COMPLETED
AMAZE™ Asthma Implementation QI Study
NCT04901260
COMPLETED
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects
NCT06015256
RECRUITING
NA
Prevalence of Hyperventilation Syndrome in Difficult Asthma
NCT01862289
COMPLETED
NA